A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...

Researchers investigate the cellular and molecular mechanisms through which stress exacerbates immunoglobulin E cutaneous allergic inflammation.

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

About Cutaneous Squamous Cell Carcinoma Cutaneous ... binds PD-L1 and blocks the interaction between PD-L1 and its T cell receptors, PD-1 and B7.1. This interaction releases the inhibitory effects ...

A novel topical gel, HT-001, shows promise as a treatment for cutaneous side effects caused by epidermal growth factor receptor inhibitor (EGFRi) cancer therapy. According to a press release ...

The FDA has approved Checkpoint Therapeutics’ Unloxcyt (cosibelimab-ipdl), a PD-L1 blocking antibody, for adults with metastatic or locally advanced cutaneous squamous cell ... rather than programmed ...